drugset
drugset / Trial / NCT04384484

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04384484 ↗

Phase 3 Active not recruiting 440 enrolled ADC Therapeutics S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy.

Timeline

Start
2020-09-16
Primary completion
2026-03-31
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Loncastuximab Tesirine Other / unclassified 75 ug/kg Intravenous
Comparator Oxaliplatin Small molecule 100 mg/m2 Intravenous
Background Rituximab Monoclonal antibody 375 mg/m2 Intravenous

Indications

diffuse large B-cell lymphoma